Carbaglu
(Carglumic Acid)PreclinicalSmall molecule
Carbaglu is one of 47 small molecule programs targeting Efficacy. It is currently in Preclinical.
1
Indications
4
Total Trials
2
Active Trials
46
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Efficacy
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Tivicay
GSKPhase 3
Rogaine
PfizerPhase 3
Rayos
RRoxane Laboratories
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Alimta
SShawn Eagle
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
QL2107
Qilu Pharmaceutical Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Observational Study1 trial
Regulatory
FDA Approval Timeline[4]
Mar 18, 2010
CARBAGLU
NDA NDA022562
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carglumic Acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RRECORDATI GROUP